Engineered immune cells take on stubborn leukemia
NCT ID NCT07336875
First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This early-phase study tests a new type of cell therapy called CAR-ITNK for people with relapsed or refractory acute myeloid leukemia (AML), a blood cancer that has not responded to standard treatments. The therapy uses specially engineered immune cells that target two proteins, CD70 and CLL1, found on leukemia cells. Up to 30 participants will receive a single infusion and be followed for three years to see if the treatment is safe and helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.